GlobeNewswire by notified

All conditions fulfilled for the partnership between Eolus and Hydro REIN to develop a portfolio of up to 672 MW wind power

Share

Hässleholm, Sweden, January 10th, 2022

On December 24th, 2021, Eolus announced that the company and Hydro REIN enters a partnership for joint development and realization of a portfolio of nine Swedish wind power projects in early development phase owned by Eolus. All conditions for the partnership agreement have been fulfilled and payment has occurred.

The portfolio which Hydro REIN have obtained 50% of consists of nine projects with an installed capacity of up to 672 MW located in SE3 and SE4 in Sweden. The projects are in early development stage and are expected to be commissioned during 2027-2032 pending all required permits being obtained.

For further information contact:

Per Witalisson, CEO, +46 70-265 16 15
Johan Hammarqvist, Head of Communications, +46 720 50 59 11

About Eolus:
Eolus Vind AB is one of the leading wind power developers in the Nordics. Eolus is active in the whole value chain from development of green field projects to construction and operation of wind farms. Eolus offers attractive and competitive investments in the Nordic and Baltic countries, Poland as well as the United States to both local and international investors. Founded in 1990, Eolus has constructed 666 wind turbines with a capacity of 1 414 MW. Eolus has signed contracts for about 1 330 MW of asset management services of which 921 MW are in operation and the rest under construction.

Eolus Vind AB has 36 500 shareholders. Eolus shares are listed at Nasdaq Stockholm.

For more information about Eolus, please visit www.eolusvind.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Handelsinvest opdaterer prospektet23.4.2024 11:22:23 CEST | pressemeddelelse

Investeringsforeningen Handelsinvest Vestergade 8-16 8600 Silkeborg Tlf. 8989 2500 handelsinvest@jyskeinvest.dk www.handelsinvest.dk Nasdaq Copenhagen A/S Nikolaj Plads 6 1007 København K23. april 2024 Opdatering af prospektet i Handelsinvest Investeringsforeningen Handelsinvest har opdateret prospektet. Der er sket følgende opdateringer/ændringer: Opdatering af data på bestyrelsesmedlemmer.Tilføjelse af ”under overflytning” og ”under fusion” i de afdelingsspecifikke afsnit.Opdatering af investeringsstrategien i afdeling Nordamerika.Sproglige tilpasninger m.m. Det opdaterede prospekt kan findes på www.handelsinvest.dk Med venlig hilsen Lone Mørch Henrik Kragh Bestyrelsesformand Director

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit23.4.2024 11:00:00 CEST | Press release

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy. Presentation Details Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo Borras, Chief Scientific Officer Date: April 23, 2024 About CDR-Life CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to

Planlagt suspension i Sparinvest SICAV23.4.2024 10:54:57 CEST | pressemeddelelse

København, April 23, 2024 (GLOBE NEWSWIRE) -- Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeEquitas EUR RLU0362354549SSIEEURREthical Global Value EUR RLU0362355355SSIEGVEURREuropean Value EUR RLU0264920413SSIEUVEURRGlobal Value EUR RLU0138501191SSIGVEURR Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze

Planlagt suspension i Investeringsforeningen Sparinvest23.4.2024 10:52:33 CEST | pressemeddelelse

Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeMix Aktier KL ADK0010014778SPIMAKLAValue Aktier KL ADK0010079631SPIVAKLAValue Europa KL ADK0060032571SPIVEUKLAValue Emerging Markets KL ADK0010304856SPIVEMKLABæredygtige Aktier Akk. KL ADK0060012896SPIBDAAKKKLAINDEX Dow Jones Sustainability World KLDK0010297464SPIDJWKLINDEX Emerging Markets KLDK0060300762SPIEMIKLINDEX Europa Growth KLDK0010297548SPIEUGKLINDEX Europa Small Cap KLDK0010297621SPIEUCKLINDEX Europa Value KLDK0010297704SPIEUVKLBæredygtige Aktier KL ADK0061294048SPIBDAGlobale Fokusaktier KL ADK0061293826SPIGFAMix Maksimum Risiko KL ADK0061551892SPIMMRIABæredygtige Value Aktier KL ADK0061551546SPIBDVAAMix Lav Risiko KL ADK0060623189SPIMLRKLAMix Mellem Risiko KL ADK0060623262SPIMMRKLAMix Høj Risiko KL ADK0060623346SPIMHRKLAMix Minimum Risiko KL ADK0060914901SPIMIXMINRISKKLA Eventuelle spørgsmål vedrørende

Delårsrapport for perioden 1. januar - 31. marts 202423.4.2024 10:47:40 CEST | pressemeddelelse

Bestyrelsen for Tivoli A/S har den 23. april 2024 behandlet og godkendt delårsrapporten for perioden 1. januar - 31. marts 2024. Tivoli åbnede sommersæsonen 22. marts, hvilket er tidligere end sidste år hvor sæsonen åbnede 31. marts. Dette påvirker resultatet for perioden som i hovedtræk er: En nettoomsætning på 90,4 mio. kr. mod 61,8 mio. kr. sidste år (+46%).Et resultat før af- og nedskrivninger (EBITDA) på -84,2 mio. kr. mod -96,7 mio. kr. sidste år.Et resultat før skat på -112,4 mio. kr. mod -126,1 mio. kr. sidste år.Et besøgstal på 221.000 mod 47.000 sidste år (+470%). ”Tivoli fortsætter den positive udvikling, vi så i 2023. Første kvartal 2024 tegner sig for et resultat svarende til det forventede, med bedre gæstetal og økonomisk resultat, end samme periode i 2023. Vi går ind i sommersæsonen med optimisme og en lang række attraktive tilbud til Tivolis gæster, som bl.a. kan se frem til en sommer med et overordentlig stærkt kulturprogram.” udtaler adm. direktør, Susanne Mørch Koch

HiddenA line styled icon from Orion Icon Library.Eye